First-line antiretroviral drug discontinuations in children

• Melony Fortuin-de Smidt,

  Affiliation Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

  ⨯
• Reneé de Waal,

  Affiliation Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

  ⨯
• Karen Cohen,

  Affiliation Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

  ⨯
• Karl-Günter Technau,

  Affiliation Empilweni Services and Research Unit, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Kathryn Stinson,

  Affiliations Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa, Médecins Sans Frontières, Khayelitsha, South Africa

  ⨯
• Gary Maartens,

  Affiliation Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

  ⨯
• Andrew Boulle,

  Affiliation Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

  ⨯
• Ehimario U. Igumbor,

  Affiliation US Centers for Disease Control and Prevention, Pretoria, South Africa

  ⨯
• Mary-Ann Davies

  * E-mail: mary-ann.davies@uct.ac.za

  Affiliation Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

  ⨯